On October 30, 2026, Healthed published “What to investigate during the menopause transition,” a clinical article addressing hormone testing and symptoms that warrant investigation. It reports commentary from Dr Karen Magraith and Dr Jane Elliott, both identified as past presidents of the Australasian Menopause Society (AMS).
Is routine hormone testing the standard approach?
The established approach already separates recognising menopause from investigating a particular symptom. Healthdirect's AMS information describes assessment in women over 45 as based on symptoms and menstrual changes rather than routine hormone measurements.
Healthed's article reinforces that position rather than announcing a new national guideline. Its focus is the distinction between a test intended to establish menopause and an investigation chosen because bleeding or fatigue needs an explanation. Recognising the hormonal transition does not close the assessment of everything happening alongside it.
Which menopause symptoms and bleeding changes need investigation?
The investigations described in the article are selected according to a woman's presentation. They are not a universal menopause testing panel. The practical question is what needs explaining, then which assessment could help a clinician explain it.
Why might hormone tests offer less clarity after 45?
- Hormone levels fluctuate during perimenopause. Dr Magraith says FSH and estradiol results can be confusing or misleading during this transition. Healthed reports that hormone testing is rarely needed for women over 45 because menopause and perimenopause are usually assessed clinically. A laboratory result is not a substitute for understanding the pattern of symptoms and menstrual changes.
- The results do not predict treatment response. Dr Magraith says FSH and estradiol measurements do not show whether someone will respond to treatment. For a clinical conversation, this separates the question of what a hormone level shows from the question of what care may suit the person's symptoms. Those are not interchangeable decisions.
- Hormone levels do not measure the burden of symptoms. Dr Elliott says levels do not correlate with the severity or duration of menopausal symptoms. The editorial implication is straightforward: a woman's account of what she is experiencing deserves attention in its own right. It should not have to be validated by a particular hormone result.
Which bleeding patterns deserve assessment?
- Bleeding that is much heavier than usual or prolonged. Healthed reports Dr Magraith's advice to investigate these changes. Describing what has changed from the woman's usual pattern gives the clinician a clearer starting point than describing the bleeding only as part of perimenopause.
- Erratic bleeding or bleeding between periods. The article identifies both as reasons for further assessment. Healthdirect's AMS information also says women over 40 with more frequent or heavy bleeding require investigation by their doctor. It gives the same advice for bleeding between periods.
- Bleeding after sex. This is another pattern Dr Magraith identifies for investigation. It deserves to be named separately in a consultation rather than grouped into a broad description of unpredictable cycles. The pattern itself is relevant information for the assessment.
- Bleeding after menopause. Both Healthed and the AMS material on Healthdirect say this needs investigation. Healthdirect describes menopause as diagnosed after 12 months without a period. Bleeding after that point should not be dismissed as another routine feature of the transition.
These are reasons to seek an explanation, not evidence that a particular condition is present. The distinction allows bleeding changes to be taken seriously without turning the need for assessment into a diagnosis.
What might a bleeding assessment involve?
- An examination and relevant cervical screening. Dr Magraith describes examination as part of an initial evaluation. A cervical screening co-test may be included where indicated. The article presents these as components of clinical assessment rather than as tests a reader needs to arrange independently.
- STI testing where appropriate. The initial assessment may include consideration of STI testing. Its inclusion illustrates why the investigation of bleeding is broader than measuring reproductive hormones: the clinician is assessing the bleeding presentation rather than simply trying to confirm a life stage.
- Pelvic ultrasound. Healthed lists ultrasound among the possible initial investigations for bleeding that warrants assessment. This is part of the pathway described by Dr Magraith. The choice belongs within the clinical evaluation of the bleeding pattern.
- Gynaecological assessment after an abnormal ultrasound. The article says an abnormal ultrasound should lead to gynaecological assessment and a decision about endometrial sampling. That wording matters: the report describes a further clinical decision, not an automatic conclusion about what an abnormal finding means.
Why might fatigue lead to different blood tests?
- Heavy bleeding or fatigue can justify targeted blood testing. Dr Magraith says a full blood count, ferritin and thyroid function tests are often warranted in these presentations. The purpose is to investigate the symptom in front of the clinician rather than seek a hormone result to explain the whole transition.
- Other conditions can sit alongside menopausal symptoms. Healthdirect's AMS information identifies anaemia and thyroid disorders in this context. It says blood count, ferritin and/or TSH testing may help establish a diagnosis in relevant presentations. This supports a broader assessment without assuming that fatigue has one explanation.
- Thyroid questions belong within that wider conversation. The overlap described by Healthdirect is a reason not to label every change as hormonal. Refemina's coverage of thyroid questions during the menopause transition provides related context for discussing symptoms with a qualified clinician.
- Other investigations depend on the presentation. Healthed also lists renal and liver function, lipids, blood glucose and vitamin D as possible tests where indicated. Their inclusion does not make them tests for establishing menopause. They sit within the article's broader discussion of assessing a woman's health concerns.
When does age change the testing question?
- Women under 40 have a different assessment context. Dr Magraith says hormone testing may be warranted in this group. She also says clinicians should consider premature ovarian insufficiency when a woman under 40 has infrequent periods. The article links identifying it with managing associated health risks and discussing treatment.
- Testing may help clarify symptoms in the early 40s. Dr Magraith describes a potential role for hormone testing in women aged 40 to 44. The AMS information on Healthdirect identifies symptomatic women under 40 and those aged 40 to 45 as groups for whom FSH measurement may be indicated.
- Absent or irregular periods may raise a separate question. Healthed says pregnancy testing may sometimes be appropriate for women with amenorrhoea or irregular cycles. This is another example of selecting an investigation for a specific clinical question rather than treating every menstrual change as proof of menopause.
What information helps make the consultation more focused?
- Describe the bleeding pattern rather than relying on a life-stage label. A useful account distinguishes heavier bleeding from longer bleeding. It also identifies bleeding between periods or after sex. Refemina's guide to period changes and clinical concerns offers wider context for that discussion.
- Mention fatigue alongside the menstrual changes. Healthed's discussion connects these presentations with targeted investigations. Bringing both into the same conversation gives the clinician the information needed to assess the overall presentation. It avoids making the consultation solely a request to confirm menopause through a hormone panel.
- Keep the clinical question specific. Asking what a proposed test is intended to investigate follows the distinction running through both sources. The answer may concern bleeding or another symptom rather than menopause itself. Understanding which healthcare professional can help with a particular concern can also help frame the conversation.
How could this shape future menopause care?
This approach should direct care toward clinical recognition of menopause and targeted investigation of bleeding or fatigue rather than routine hormone panels.
How Refemina helps
Having a bleeding concern assessed is a concrete health outcome; Refemina offers research-led explanations that connect hormonal change with women's wider lives. For readers whose unpredictable physical changes have unsettled their sense of identity, the publication brings confidence and reinvention into the discussion without turning every midlife concern into a hormone or supplement opportunity.
Explore Resources
Sources
- What to investigate during the menopause transition - Healthed
- Contraception options - types, finding the best birth control ...
